Dr. Wayne Batchelor is President of the Medicine Service Line at the Inova Health System in Fairfax, Virginia; Schar Chair of the Inova Schar Heart and Vascular Institute; and Professor (adj.) of Medicine at the Duke University School of Medicine. He is an internationally recognized interventional cardiologist, physician executive, clinical investigator, and educator.  Dr. Batchelor serves on the Society for Cardiovascular Angiography and Interventions (SCAI) Broadening Opportunity, Leadership, and Delivery of Patient Care (BOLD) Committee and the JSCAI Advisory Committee and Editorial Board.  He is also Immediate-Past Chair of the American College of Cardiology (ACC) Interventional Cardiology Section Leadership Council and incoming Chair of the Society of Thoracic Surgery (STS)/ACC Transcatheter Valve Therapy (TVT) Registry within the National Cardiovascular Data Registry (NCDR).  Prior to his current role, Dr. Batchelor served as Associate Director of the Inova Schar Heart and Vascular Institute and System Director of Interventional Cardiology and Interventional Research.  A leading authority in structural heart disease, complex and high-risk percutaneous coronary intervention (PCI), cardiogenic shock, clinical trial design, and healthcare disparities, Dr. Batchelor has authored more than 250 peer-reviewed publications, multiple book chapters, and has served as National Principal Investigator or Steering Committee member for several pivotal clinical trials. He is a frequently invited speaker at international scientific meetings, Senior Advisor to the Journal of the American College of Cardiology (JACC), and serves on the Editorial Boards of Circulation, JSCAI, the Structural Heart Journal, and Cardiovascular Revascularization Medicine. In 2024, he earned an Executive MBA from the NYU Stern School of Business, where he was awarded the Advancing Diversity in Business Academic Merit Scholarship. Dr. Batchelor also serves as a Special Government Employee and consultant to the U.S. Food and Drug Administration (FDA) within the Cardiovascular Devices Branch, where he helps guide the regulatory science of cardiovascular device trials.